Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Erikson's Theory on Socioemotional Development during Childhood
The first four of Erikson's eight...
Piaget's Theory of Cognitive Development from Childhood into Adulthood
Schemata: Building Blocks of Knowledge
Control System Problem
When forming a closed-loop system, issues can arise if the poles cross into the unstable region, leading to potential...
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Control Systems
At the heart...
Telitacicept for childhood HSPN: A prospective self-controlled study.
Hanhan Zhang1, Dan Song2, Ke Song1
1Pediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
View abstract on PubMed
Telitacicept (RC18) effectively treats Henoch-Schönlein Purpura Nephritis (HSPN) in children by reducing urine protein and red blood cells. This study confirms its good clinical effects and safety profile for pediatric HSPN management.
Area of Science:
- Pediatric Nephrology
- Immunology
- Rheumatology
Background:
- Henoch-Schönlein Purpura Nephritis (HSPN) is a common vasculitis affecting children, characterized by kidney inflammation.
- Current treatments for HSPN often have limitations, necessitating the exploration of novel therapeutic agents.
- Telitacicept (RC18) is an emerging biologic agent with potential immunomodulatory effects.
Purpose of the Study:
- To evaluate the efficacy and safety of Telitacicept (RC18) in pediatric patients diagnosed with HSPN.
- To assess the impact of Telitacicept on key clinical and laboratory markers of HSPN.
- To explore the potential mechanisms of action of Telitacicept in HSPN treatment.
Main Methods:
- A prospective, self-controlled study involving children with HSPN.
Main Results:
- Telitacicept demonstrated a 100% response rate for 24-hour UTP and a 66.7% response rate for urine RBC count.
- Significant reductions in 24-hour UTP and urinary RBC count were observed post-treatment (P<0.01).
- Renal function remained stable, and no serious adverse reactions were reported, though minor biochemical and injection site reactions occurred.
Conclusions:
- Telitacicept (RC18) is effective in reducing proteinuria and hematuria in children with HSPN.
- The treatment shows a favorable safety profile, making it a promising option for pediatric HSPN.
- Preliminary findings suggest Telitacicept may modulate lymphocyte populations and Gd-IgA1 levels in HSPN.


